Publications

Technology Platform

Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies

Bowers et al. Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20455-60. doi:10.1073/pnas.1114010108

Mammalian cell display for the discovery and optimization of antibody therapeutics

Bowers et al. Methods. 2014 Jan 1;65(1):44-56. doi:10.1016/j.ymeth.2013.06.010

Humanization of Antibodies Using Heavy Chain Complementarity-determining Region 3 Grafting Coupled with in Vitro Somatic Hypermutation

Bowers et al. J Biol Chem. 2013 Mar 15;288(11):7688-96. doi:10.1074/jbc.M112.445502

High Affinity Humanized Antibodies without Making Hybridomas; Immunization Paired with Mammalian Cell Display and In Vitro Somatic Hypermutation

McConnell et al. PLOS ONE. 2012;7(11):e49458. doi:10.1371/journal.pone.0049458

AID-induced insertions and deletions complement point mutations to massively expand the diversity created by somatic hypermutation of antibodies

Verdino et al. Poster presented at Keystone Symposium on Antibodies as Drugs 2015.

The Biochemistry of Somatic Hypermutation

Peled et al. Annu Rev Immunol. J Exp Med. 2005 May 2;201(9):1467-78. doi:10.1146/annurev.immunol.26.021607.090236

Intricate targeting of immunoglobulin somatic hypermutation maximizes the efficiency of affinity maturation

Zheng et al. J Exp Med. 2005 May 2;201(9):1467-78. doi:10.1084/jem.20042483

Generation and iterative affinity maturation of antibodies in vitro using hypermutating B-cell lines

Cumbers et al. Nat Biotechnol. 2002 Nov;20(11):1129-34. doi:10.1038/nbt752

ANB020

IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy

Cayrol et al. Curr Opin Immunol. 2014 Dec;31:31-7. doi:10.1016/j.coi.2014.09.004

Resolution of Allergic Inflammation and Airway Hyperreactivity Is Dependent upon Disruption of the T1/ST2–IL-33 Pathway

Kearley et al. Am J Respir Crit Care Med. 2009 May 1;179(9):772-81. doi:10.1164/rccm.200805-666OC

Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma

Liu et al. Biochem Biophys Res Commun. 2009 Aug 14;386(1):181-5. doi:10.1016/j.bbrc.2009.06.008

Decoding asthma: Translating genetic variation in IL33 and IL1RL1 into disease pathophysiology

Grotenboer et al. J Allergy Clin Immunol. 2013 Mar;131(3):856-65. doi:10.1016/j.jaci.2012.11.028

Functional analysis of protective IL1RL1 variants associated with asthma risk

Ramirez-Carrozzi et al. J Allergy Clin Immunol. 2015 Apr;135(4):1080-3.e3. doi:10.1016/j.jaci.2014.10.028

IL-33 and ST2 in Atopic Dermatitis: Expression Profiles and Modulation by Triggering Factors

Savinko et al. J Invest Dermatol. 2012 May;132(5):1392-400. doi:10.1038/jid.2011.446

Increased Expression of IL-33 in Severe Asthma: Evidence of Expression by Airway Smooth Muscle Cells

Préfontaine et al. J Immunol. 2009 Oct 15;183(8):5094-103. doi:10.4049/jimmunol.0802387

ANB019

IL-36 in psoriasis

Towne et al. Curr Opin Pharmacol. 2012 Aug;12(4):486-90. doi:10.1016/j.coph.2012.02.009

IL-36: a potential psoriasis target?

Raison et al. Expert Rev Dermatol. 2012 7(6):503-505. doi:10.1586/EDM.12.65

Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis

Marrakchi et al. N Engl J Med. 2011 Aug 18;365(7):620-8. doi:10.1056/NEJMoa1013068

Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis

Onoufriadis et al. Am J Hum Genet. 2011 Sep 9;89(3):432-7. doi:10.1016/j.ajhg.2011.07.022

The Majority of Generalized Pustular Psoriasis without Psoriasis Vulgaris Is Caused by Deficiency of Interleukin-36 Receptor Antagonist

Sugiura et al. J Invest Dermatol. 2013 Nov;133(11):2514-21. doi:10.1038/jid.2013.230

IL-1F5, -F6, -F8, and -F9: A Novel IL-1 Family Signaling System That Is Active in Psoriasis and Promotes Keratinocyte Antimicrobial Peptide Expression

Johnston et al. J Immunol. 2011 Feb 15;186(4):2613-22. doi:10.4049/jimmunol.1003162

Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammation

Blumberg et al. J Exp Med. 2007 Oct 29;204(11):2603-14. doi:10.1084/jem.20070157

Immuno-Oncology

Identification and characterization of TSR-042, a novel anti-PD-1 therapeutic antibody

Laken et al. Poster presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2016.

Discovery of TSR-022, a novel, potent anti-TIM-3 therapeutic antibody

Laken et al. Poster presented at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2016.

Targeting PD-1, TIM-3 and LAG-3 in Combination for Improved Immunotherapy Combinations

Kehry et al. Poster presented at AACR Annual Meeting 2015.

Generation of anti-LAG-3 monoclonal antibodies for use in immunotherapy combinations

Jun et al. Poster presented at Keystone Symposium on Antibodies as Drugs 2015.

Identification and Characterization of a Potent Anti-Human Tim-3 Antagonist

Correia et al. Poster presented at AACR Special Conference on Tumor Immunology and Immunotherapy 2014.

Generation of antagonistic anti-TIM-3 and LAG-3 monoclonal antibodies for potential novel immunotherapy combinations

Jun et al. Poster presented at AACR Annual Meeting 2014.